GHP November 2017 - Texas A&M

2 GHP / November 2017 Editor’s Note , Welcome to the November edition of GHP Magazine, providing you with a diverse range of news and exciting features. In recent news, a late-stage life sciences investment firm that partners with companies to successfully bring novel medical therapies to market, Aisling Capital announced on the 2nd November the closing of its newest fund, with $280 million in committed capital. The capital raised will allow Aisling Capital to continue helping clinical stage ventures improve global health by more rapidly bringing breakthrough medical treatments to market. Gracing the cover of this month’s issue, Texas A&M is one of the largest universities in the United States of America, with a current student body of more than 60,000 and a physical campus of more than 5,200 acres. We profiled the University in order to explore the secrets behind its success and what will help it go further in the future. Speaking of success, founded in 2009, Cytosurge has invested considerable time and money to turn a laboratory idea into a commercially viable technology. We profiled the firm in order to find out what clients can expect when working with the company. Lastly, we discover more about independent, internationally recognized health care accrediting body, Accreditation Commission for Health Care (ACHC). The organisation is focused on helping providers demonstrate compliance with applicable standards of practice and care. We learn more about accrediting body when we spoke to ACHC President and CEO, José Domingos to find out more about ACHC’s compliance solutions. Here at GHP Magazine, we hope that you truly enjoy reading this edition and look forward to hearing from you soon. Jessie Daykin, Editor Phone: +44 (0) 203 725 6842 Email: j.dayki [email protected] Website: AI Global Media, Ltd. (AI) takes reasonable measures to ensure the quality of the information on this web site. However, AI will not assume any legal liability or responsibility for the accuracy, correctness or completeness of any information that is available through this web site. If errors are brought to our attention, we will try to correct them. The information available through the website and our partner publications is for your general information and use and is not intended to address any particular finance or investment requirements. In particular, the information does not constitute any form of advice or recommendation by us or any of our partner publications and is not intended to be relied upon by users in making or refraining from making any investment or financial decisions. Appropriate independent advice should be obtained before making any such decision. Any arrangement made between you and any third party named in the site is at your sole risk and responsibility.